The efficacy and safety of atezolizumab, nivolumab, and pembrolizumab as second-line therapy for non-small-cell lung cancer: preliminary data

Close metadata

Objective was publication sum concerning efficacy and safety of atezolizumab, nivolumab, pembrolizumab and docetaxel in second-line treatment of non-small-cell lung cancer (NSCLC). Aim was to determine and compare the atezolizumab, nivolumab and pembrolizumab efficiency and safety integral parameters in second-line NSCLC. Comparative analysis of the several checkpoint PD-L1/PD-1 inhibitors was undertaken. Deterioration due to parameters variability was too high, so the homogeneous groups combination and following meta-analysis increased statistical power of the research. Efficiency of atezolizumab was the best in comparisons nivolumab, pembrolizumab and docetaxel overall and progression-free survival. Also atezolizumab had the best safety in frequencies of autoimmune adverse effects against others checkpoint PD-1/ PD-L1 inhibitors.

Keywords:

non-small-cell lung cancer

atezolizumab

nivolumab

pembrolizumab

docetaxel

PD-1 receptor

PD-L1 ligand

metaanalysis

odds ratio

Authors:

Mazina N.K.

Kirov State Medical Academy, Kirov

Mazin P.V.

Kirov State medical Academy, Kirov, Russia

List of references:

Aguiar PNJr, De Mello RA, Barreto CMN, Perry LA, Penny-Dimri J, Tadokoro H, Lopes GLJr. Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. ESMO Open. 2017;2(3):e000200. https://doi.org/10.1136/esmoopen-2017-000200
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504-535.
Kaprin AD, Starinskii VV, Petrova GV, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2016 (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ.)
Kaprin AD, Starinskii VV, Petrova GV, eds. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMIRTs» Minzdrava Rossii; 2016. (In Russ.)
Iafolla M, Juergens R. Update on programmed death-1 and programmed death-ligand 1 inhibition in the treatment of advanced or metastatic non-small cell lung cancer. Front Oncol. 2017;7:67. https://doi.org/10.3389/fonc.2017.00067
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. https://doi.org/10.1056/NEJMoa1507643
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135. https://doi.org/10.1056/NEJMoa1504627
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. https://doi.org/10.1056/NEJMoa1501824
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, et al. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non small cell lung cancer. ESMO Open. 2017;1(4):e000108. https://doi.org/10.1136/esmoopen-2016-000108
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, et al. Phase II Trial of Atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1 selected advanced non-small cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781-2789. https://doi.org/10.1200/JCO.2016.71.9476
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-265. https://doi.org/10.1016/S1470-2045(15)70054-9
Chow J, Cheung K, Cho W. Atezolizumab in non-small-cell lung cancer: the era of precision immuno-oncology. Ann Transl Med. 2017;5(12):265. https://doi.org/10.21037/atm.2017.03.89
Ramos-Esquivel A, van der Laat A, Rojas-Vigott R, Juárez M, et al. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open. 2017;2(3):e000236. https://doi.org/10.1136/esmoopen-2017-000236
Créquit P, Chaimani A, Yavchitz A, Attiche N, Cadranel J, Trinquart L, Ravaud P. Comparative efficacy and safety of second-line treatments for advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network metaanalysis. BMC Med. 2017;15(1):193. https://doi.org/10.1186/s12916-017-0954-x
Khafiz’yanova RKh, Burykin IM, Aleeva GN. Matematicheskaya statistika v eksperimental’noi i klinicheskoi farmakologii. Kazan’: Meditsina; 2006. (In Russ.)
Vlasov VV. Epidemiologiya. Moscow: GEOTAR-Media; 2005. (In Russ.)
Petrov VI. Bazisnye printsipy i metodologiya dokazatel’noi meditsiny. Vestnik VolgGMU. 2011;(2):3-8. (In Russ.)
Petrov VI, Nevdogoda SV. Meditsina, osnovannaya na dokazatel’stvakh. Moscow: GEOTAR-Media; 2009. (In Russ.)
Rebrova OYu. Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA. Moscow: Media Sfera; 2002. (In Russ.)
Fletcher R, Fletcher S, Wagner E. Clinical epidemiology. The essentials. 3rd ed. Baltimore: Williams and Wilkins; 1996.
Moore A, McQuay H. Chto takoe NNT? Klinicheskaya farmakologiya i terapiya. 2000;9(Pt2):84-86. (In Russ.)
Effect Size. Available at: https://www.campbellcollaboration.org/escalc/html/ EffectSize Calculator-OR1.php. Accessed 10-16 January 2018.
Kanai O, Nakatani K, Fujita K, Okamura M, Mio T. Concurrence of Nivolumab-induced interstitial lung disease and cancer invasion. Respirol Case Rep. 2017;5(6):e00257. https://doi.org/10.1002/rcr2.257
Manapov F, Roengvoraphoj O, Dantes M, Marschner S, Li M, EzeC. Pneumonitis in irradiated lungs after Nivolumab: a brief communication and review of the literature. J Immunother. 2018;41(2):96-99. https://doi.org/10.1097/CJI.0000000000000198
Salati M, Pifferi M, Baldessari C, Bertolini F, Tomasello C, Cascinu S, Barbieri F. Stevens-Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol. 2018;29(1):283-284. https://doi.org/10.1093/annonc/mdx640
Godwin JL, Jaggi S, Sirisena I, Sharda P, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017;5:40.
Turgeman I, Wollner M, Hassoun G, Bonstein L, Bar-Sela G. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anticancer Drugs. 2017;28(7):811-814. https://doi.org/10.1097/CAD.0000000000000520
Khan U, Rizvi H, Sano D, Chiu J, et al. Nivolumab induced myxedema crisis. J Immunother Cancer. 2017;5:13.
Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid. 2017;27(7):894-901. https://doi.org/10.1089/thy.2016.0562
Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs. 2018;36(1):144-146.
Sugiura Y, Fujimoto H, Yamamoto M, Nomura H, Hashizume T, Kawai O, Araki N, Kawakami K, Sueki H, Fusegawa H, Ohkubo Y, Nemoto E. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer. Gan To Kagaku Ryoho. 2017;44(9):787-789.
Richard K, Weslow J, Porcella SL, Nanjappa S. A case report of steroid responsive nivolumab-induced encephalitis. Cancer Control. 2017;24(5):107327481779069. https://doi.org/10.1177/1073274817729069
Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, et al. Analysis of early death in Japanese patients with advanced non-small-cell lung cancer treated with nivolumab. Clin Lung Cancer. 2018;19(2):e171-e176. https://doi.org/10.1016/j.cllc.2017.09.002
Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102(8):2770-2780. https://doi.org/10.1210/jc.2017-00448
González Vázquez S, de la Riva Onandía S, Echeveste JI, Muñoz Navas M. Immune mediated colitis caused by lung cancer treatment with atezolizumab. Rev Esp Enferm Dig. 2017;109(12):863-864.
Goryainov SV, Rebrova OYu. Nepryamye sravneniya v otsenke meditsinskikh tekhnologii. Meditsinskie tekhnologii. Otsenka i vybor. 2011;(3):9-12. (In Russ.)

Close metadata